What is ABECMA? ABECMA (idecabtagene vicleucel) is a prescription medicine for the treatment of multiple myeloma in patients who have received at least four kinds of treatment regimens that have not worked or have stopped working. ABECMA is a medicine made from your own white blood cells; the cells are genetically modified to recognize and attack your multiple myeloma cells.

This website is best viewed using the horizontal display on your tablet device.

This website is best viewed using the vertical display on your mobile device.

Cell Therapy 360® logo

Cell Therapy 360®:
Your partner
throughout the CAR T
therapy treatment

CAR=chimeric antigen receptor.

Cell Therapy 360 offers assistance programs
for you and your care partner that are
designed to support you throughout
treatment and the initial post-infusion
monitoring period (at least 4 weeks).

A dedicated Patient
Support Navigator
Financial support

Eligibility requirements apply.

visit cell therapy 360

You may enroll in support programs after a certified CAR T cell therapy treatment center determines that ABECMA® is the right treatment for you.

The services and support programs offered through Cell Therapy 360 are available only to people who are receiving a CAR T cell therapy from Bristol Myers Squibb, such as ABECMA. Certain restrictions and eligibility requirements apply.

To learn more about the support program offerings
available through Cell Therapy 360:

  • Talk to your healthcare team for more information
  • Visit CellTherapy360.com
  • Call 1-888-805-45551-888-805-4555 (available Monday through Sunday, 24 hours a day)